KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Non-Current Debt (2019 - 2025)

Rigel Pharmaceuticals has reported Non-Current Debt over the past 7 years, most recently at $52.3 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 12.38% year-over-year to $52.3 million; the TTM value through Dec 2025 reached $52.3 million, down 12.38%, while the annual FY2025 figure was $52.3 million, 12.38% down from the prior year.
  • Non-Current Debt for Q4 2025 was $52.3 million at Rigel Pharmaceuticals, up from $30.0 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $59.8 million in Q3 2024 and troughed at $19.8 million in Q1 2021.
  • A 5-year average of $41.9 million and a median of $42.2 million in 2022 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: surged 101.89% in 2021 and later plummeted 49.85% in 2025.
  • Year by year, Non-Current Debt stood at $19.9 million in 2021, then skyrocketed by 98.09% to $39.4 million in 2022, then soared by 32.76% to $52.4 million in 2023, then grew by 13.95% to $59.7 million in 2024, then dropped by 12.38% to $52.3 million in 2025.
  • Business Quant data shows Non-Current Debt for RIGL at $52.3 million in Q4 2025, $30.0 million in Q3 2025, and $37.5 million in Q2 2025.